Keyphrases
COVID-19
100%
Ongoing Clinical Trials
100%
Coronavirus
40%
Repurposing
40%
Epidemiology
20%
Virus
20%
Therapeutic Agents
20%
Epidemiological Data
20%
Clinical Trials
20%
Disease Presentation
20%
Therapeutic Potential
20%
Design Approach
20%
Effective Approach
20%
Clinical Data
20%
Rapid Response
20%
Inflammatory Response
20%
High Variability
20%
Human Society
20%
Health Systems
20%
Molecular Characteristics
20%
Big Data Analysis
20%
Clinical Features
20%
Global Economy
20%
Drug Repurposing
20%
Viral Replication
20%
Dysregulated
20%
Virus Infection
20%
Treatment Control
20%
Wuhan
20%
Virus Replication Cycle
20%
Therapeutic Antibody
20%
Hydroxychloroquine
20%
Response Measures
20%
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
20%
COVID-19 Pandemic
20%
SARS-CoV-2 Genome
20%
Wuhan China
20%
Global Pandemic
20%
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
20%
Antiviral Immune Response
20%
Entry Route
20%
Antimalarial Drugs
20%
Epidemiological Control
20%
Innate Antiviral
20%
Endosomal Entry
20%
Vaccine Antibodies
20%
Favipiravir
20%
Pandemic Emergency
20%
Broad-spectrum Antivirals
20%
Medicine and Dentistry
Clinical Trial
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Virus Replication
33%
Immunotherapy
16%
Clinical Feature
16%
Clinical Study
16%
Serositis
16%
Antivirus Agent
16%
Virus Infection
16%
Hydroxychloroquine
16%
Therapeutic Agent
16%
COVID-19
16%
SARS Coronavirus
16%
Drug Repositioning
16%
Middle East Respiratory Syndrome Coronavirus
16%
Coronavirinae
16%
Epidemiology
16%
Coronavirus
16%
Antimalarial Agent
16%
Favipiravir
16%
Antiviral Immune Response
16%
Diseases
16%
Virus
16%
Pandemic
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
SARS Coronavirus
100%
Antivirus Agent
40%
Pandemic
40%
Coronavirinae
40%
Inflammation
20%
Immunotherapy
20%
Virus Infection
20%
Clinical Study
20%
Clinical Feature
20%
Drug Repositioning
20%
Hydroxychloroquine
20%
Repurposing
20%
Middle East Respiratory Syndrome Coronavirus
20%
Antimalarial Agent
20%
Favipiravir
20%
Diseases
20%